1. THU0173 Long term safety and efficacy of filgotinib in a phase 2B open label extension study in patients with rheumatoid arthritis: results up to 144 weeks. (15th June 2017) Authors: Alten, R; Westhovens, R; Kavanaugh, A; Genovese, M; Winthrop, K; Greenwald, M; Ponce, L; Enriquez, F; Stanislavchuk, M; Mazur, M; Spindler, A; Cseuz, R; Nikulenkova, N; Glowacka-Kulesz, M; Szombati, I; Dudek, A; Meuleners, L; Tasset, C; Harrison, P; Aa, A Van der Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 267 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗